Stifel lowered the firm’s price target on Inspire Medical (INSP) to $140 from $175 and keeps a Hold rating on the shares. With 2025 revenue stepping down, partially as a function of INSP V facility activations lagging, management remains upbeat that some of its current issues are transitory and is pointing to revenue growth accelerating next year, but the firm remains cautious and lowers its “already Street-low 2026 estimate,” the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical downgraded to Hold from Buy at Truist
- Inspire Medical downgraded to Neutral from Overweight at JPMorgan
- Inspire Medical downgraded to Sector Weight from Overweight at KeyBanc
- Inspire Medical Systems Reports Q2 2025 Financials
- Closing Bell Movers: Palantir hits record highs on beat and raise